The Diabetes Cardiovascular Disease (CVD) risk score tool was developed as a simple method to illustrate the risk of developing a major adverse cardiovascular event (MACE) amongst type 2 diabetes patients at high cardiovascular risk. The Diabetes CVD Risk Score tool is based on actual data from the LEADER trial, a cardiovascular outcomes trial. In the LEADER trial, MACE was the composite primary outcome and defined as time to first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke.
By adjusting the 11 CVD risk factors in the app (age, HbA1c, diabetes duration, BMI, systolic blood pressure, sex, insulin use, history of heart failure, history of myocardial infarction or stroke, renal disease status and smoking status), the Diabetes CVD risk score tool displays a patient’s risk in percent of experiencing a MACE within a time frame of 3 years.
The purpose of the Diabetes CVD risk score tool is to illustrate the risk of MACE within a patient population with the same characteristics. The tool cannot be used to provide a “true” risk estimate for an individual patient. As such, the tool is solely for information purposes, not for diagnosis or treatment purposes, and should not be relied on as the basis for any decision or action.
By adjusting the 11 CVD risk factors in the app (age, HbA1c, diabetes duration, BMI, systolic blood pressure, sex, insulin use, history of heart failure, history of myocardial infarction or stroke, renal disease status and smoking status), the Diabetes CVD risk score tool displays a patient’s risk in percent of experiencing a MACE within a time frame of 3 years.
The purpose of the Diabetes CVD risk score tool is to illustrate the risk of MACE within a patient population with the same characteristics. The tool cannot be used to provide a “true” risk estimate for an individual patient. As such, the tool is solely for information purposes, not for diagnosis or treatment purposes, and should not be relied on as the basis for any decision or action.
Show More
